Navigation Links
$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug
Date:4/22/2014

LOS ANGELES (April 22, 2014) Cedars-Sinai stroke intervention researchers have been informed that the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, will award an $8 million grant to fund a multicenter Phase II clinical trial of an experimental drug for stroke.

The drug, 3K3A-APC, will be used in combination with recombinant tissue plasminogen activator, or rtPA the "clot-busting" drug currently approved to treat ischemic strokes shortly after onset. In laboratory rodent studies, 3K3A-APC, used in combination with rtPA, had a protective effect on the lining of blood vessels, eliminating hemorrhaging, reducing brain damage, and improving animals' mobility after stroke. The new drug has completed a Phase I trial in 64 healthy volunteers to assess safety and dosing levels.

Ischemic strokes block arteries, depriving the brain of oxygen. The existing clot-buster, rtPA, may restore blood flow and often reverse the effects of a stroke if administered within three hours after symptoms begin. The drug, however, increases risk of internal bleeding in some patients, which can have brain-injuring and other harmful effects.

"Stroke is the fourth leading cause of death in the United States and a leading cause of disability, often leaving people to live out their lives with limited cognitive and physical skills. When patients receive rtPA within the three-hour time frame, the beneficial effects are often dramatic. But the drug is not without its limitations and potential side effects. Our objective in this and other studies is to spare more lives and livelihoods by making treatments more effective with fewer risks," said Patrick Lyden, MD, chair of Cedars-Sinai's Department of Neurology, director of the Stroke Program and the Carmen and Louis Warschaw Chair in Neurology.

The Phase II study will evaluate safety, tolerability and activity of 3K3A-APC when given after rtPA in patients who have experienced moderately severe ischemic stroke. The drug will be given intravenously as a 15-minute infusion every 12 hours for up to five treatments, and four dose levels will be evaluated. About 100 participants, ages 18 to 80, will be followed for 90 days.

APC activated protein C is a naturally occurring enzyme in the body that reduces inflammation, protects against cell death and acts as a blood thinner to prevent clotting. The drug 3K3A-APC is a synthesized and slightly modified protein that maintains APC's cell-protective and anti-inflammatory benefits while reducing anticlotting activity. It is designed, therefore, to protect brain cells and cerebral blood vessels while reducing the risk of treatment-related bleeding.

The clinical trial grant was awarded to Lyden, the study's principal investigator. He was also principal investigator of the Phase I trial and a major contributor to the clinical trial leading to Food and Drug Administration approval in 1996 of rtPA, still the only proven and approved drug for stroke treatment.

The award is also in conjunction with a NeuroNEXT Infrastructure Resource Access award to ZZ Biotech LLC, the company developing 3K3A-APC. Kent Pryor, PhD, the company's chief operating officer, will be the principal investigator for this aspect of the study. ZZ Biotech will also enlist the collaboration of NeuroNEXT, a research network funded by the National Institute of Neurological Disorders and Stroke.

The institute created NeuroNEXT the Network for Excellence in Neuroscience Clinical Trials to increase its ability to explore promising treatments by partnering with academia, private foundations and industry. With this support, the researchers will have access to the NeuroNEXT Clinical Coordinating Center at Massachusetts General Hospital and Data Coordinating Center at the University of Iowa. The University of Rochester in New York will provide a central laboratory, and about 15 NeuroNEXT centers will participate in the study.

The new drug originated in the laboratory of John Griffin, PhD, professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute, which licensed development rights to ZZ Biotech.

Berislav Zlokovic, director of the Zilkha Neurogenetic Institute and professor and chair of the Department of Physiology and Biophysics at Keck School of Medicine of the University of Southern California, and scientific founder of ZZ Biotech, will be a co-investigator of the Phase II trial.

ZZ Biotech is a company developing APC and related products for stroke and other neurological disorders. Zlokovic is the scientific founder, Pryor is the chief operating officer, Griffin is a member of the scientific advisory board and Lyden is a consultant.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
4. $9 million grant awarded to UH to study, treat learning disabilities
5. New report shows 15 million babies born too soon every year
6. Southeast program to fight diabetes awarded nearly $10 million by HHS
7. OHSU study: Misdiagnosis of MS is costing health system millions per year
8. Enzyme corrects more than 1 million faults in DNA replication
9. 53 million Americans might have diabetes by 2025, according to a new study in Population Health Management
10. Asthma Cases Continue to Rise in U.S., Affecting Millions
11. UC San Diego Superfund Research Program receives $15 million grant renewal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American ... percent of parents report speaking with their child about sex related topics, less than ... , Mediaplanet is proud to announce the launch of its second edition of the ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... 2016 , ... On November 24th, 2016, Thanksgiving morning, Branches ... sites throughout Miami-Dade and Broward counties. This is the largest meal delivery effort ... morning by putting together individual meals via assembly lines and passing them off ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge dentists, ... dental plan for all patients. Understanding that budget can play a part in ... number of perks, including discounts on many valuable dental treatments. Options for individuals, ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent policy debates, ... of public policymakers and system stakeholders in many states. To help them understand ... Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... YORK , December 2, 2016 ... 5,251.11, down 1.36%; the Dow Jones Industrial Average edged 0.36% ... at 2,191.08, down 0.35%. Losses were broad based as six ... Stock-Callers.com has initiated research reports on the following Services equities: ... (NASDAQ: QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... 2016 The concept of rare diseases and the ... this sector has been taking shape in Europe ... aspects and initiatives related to orphan medicinal products have been ... of member states individually. Many member states in the EU ... of orphan medicinal products, the result of which took the ...
(Date:12/2/2016)... -- Around the corners of world, cancer has infused ... present over earth. Cancer has become one of those ... time this is because of the increasing incidence rates ... steady increase in global cancer incidence with its associated ... of treatment, there is increasing interest in this stringent ...
Breaking Medicine Technology: